Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRef
2.
Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE (1991) P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49(5):696–703CrossRef
3.
Dunleavy K, Pittaluga S, Maeda LS et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416CrossRef
4.
Giulino-Roth L, O’Donohue T, Chen Z et al (2017) Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 179(5):739–747CrossRef
5.
Ganesan P, Ganesan TS, Atreya H et al (2018) DA-EPOCH-R in aggressive CD 20 positive B cell lymphomas: real-world experience. Indian J Hematol Blood Transf 34(3):454–459CrossRef
6.
Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRef
7.
Giulino-Roth L (2018) How I treat primary mediastinal B-cell lymphoma. Blood 132(8):782–790CrossRef
8.
Zinzani PL, Broccoli A, Casadei B et al (2015) The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol 33(4):145–150CrossRef
9.
Gleeson M, Hawkes EA, Cunningham D et al (2016) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol 175(4):668–672CrossRef
10.
Aoki T, Izutsu K, Suzuki R et al (2013) Novel prognostic model of primary mediastinal large B-cell lymphoma (PMBL): a multicenter cooperative retrospective study in Japan. ASH Annu Meet Abstr 122(21):638
Metadata
Title
Primary Mediastinal B Cell Lymphoma: A Limited Institutional Experience with Uniform DAEPOCH-R Protocol
Authors
Ajay Gogia
Sudhir Kumar
Santosh Kumar Chellapurum
Ahitagni Biswas
Soumya Mallick
Publication date
01-01-2021
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01301-z

Other articles of this Issue 1/2021

Indian Journal of Hematology and Blood Transfusion 1/2021 Go to the issue

Correspondence

COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes

Consensus Document

Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic

Original Article

Prognostic Impact of Serum Growth Differentiation Factor 15 Level in Acute Myeloid Leukemia Patients

Original Article

Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET–CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma

Original Article

Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case–Control Study

Correspondence

The Journey of Primary Myelofibrosis to Splenic Marginal Zone Lymphoma on the Wheels of Ruxolitinib
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits